Compare Incyte Corporation (INCY) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Carparts.Com Inc — how do they compare? Incyte Corporation trades at $120.67 (market cap $24.54B), while Carparts.Com Inc trades at $6.37 (market cap $51.67M). The key difference: Incyte Corporation is far larger — about 474.9× Carparts.Com Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals.
| INCY | PRTS | |
|---|---|---|
Market Cap | $24.54B | $51.67M |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $11.40 |
52-Week Low | $81.61 | $3.88 |
Enterprise Value | $20.04B | $66.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
PRTS trades at $6.35, up 0.47% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings that beat expectations, with a net loss of -$0.43 per share versus -$0.85 expected. However, fundamentals show declining revenue from $676M in 2023 to $548M in 2025 and negative net income margins. A reverse stock split was executed on May 26, 2026, to maintain Nasdaq compliance.
The outlook is mixed: analyst consensus is 60% buy with no sell ratings, but persistent losses and negative cash flow from operations pose significant risks. Investment opportunity hinges on operational turnaround and proprietary data leverage, while high volatility and competitive pressures require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
